Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior weight loss and glycemic control compared to placebo, semaglutide, and insulin in patients with type 2 diabetes and obesity.
Tirzepatide is a once-weekly injection for type 2 diabetes and obesity that works by mimicking two gut hormones (GLP-1 and GIP). It is more effective than single-hormone drugs and insulin for lowering blood sugar and losing weight. Common side effects like nausea usually improve over time. It is not for type 1 diabetes or those with a history of pancreatitis.
In clinical studies, SURPASS has shown good efficacy in reducing glycated hemoglobin and reducing weight. It therefore appears to be a promising drug both in the treatment of type 2 DM and obesity.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS-1 through 5, SURMOUNT-1) with large sample sizes and statistically significant results.
Source
Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug
Robert Prosecký et al. · Klinická farmakologie a farmacie · 2023
DOI 10.36290/far.2023.012
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →